相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Modulation of rifampicin-induced hepatotoxicity using poly(lactic-co-glycolic acid) nanoparticles: a study on rat and cell culture models
Helal F. Hetta et al.
NANOMEDICINE (2020)
A study on polymorphic forms of rifampicin for inhaled high dose delivery in tuberculosis treatment
Prakash Khadka et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2020)
High-Dose Rifampin: Shall We Be Bolder?
Kelly E. Dooley
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections
Mohammad A. M. Momin et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
Inhalation of Respirable Crystalline Rifapentine Particles Induces Pulmonary Inflammation
Thaigarajan Parumasivam et al.
MOLECULAR PHARMACEUTICS (2017)
Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis
Tejal Rawal et al.
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY (2017)
Protective Effect of Bicyclol on Anti-Tuberculosis Drug Induced Liver Injury in Rats
Xin Liu et al.
MOLECULES (2017)
Sex-specific reference intervals of hematologic and biochemical analytes in Sprague-Dawley rats using the nonparametric rank percentile method
Qili He et al.
PLOS ONE (2017)
Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
Omamah Alfarisi et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Pulmonary Pharmacokinetics of Colistin following Administration of Dry Powder Aerosols in Rats
Yu-Wei Lin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis
Tejal Rawal et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2017)
Toxicity of orally inhaled drug formulations at the alveolar barrier: parameters for initial biological screening
Eleonore Froehlich
DRUG DELIVERY (2017)
Amorphous powders for inhalation drug delivery
Lan Chen et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Evaluation of Proinflammatory Cytokines and Adverse Events in Healthy Volunteers upon Inhalation of Antituberculosis Drugs
Teerapol Srichana et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2016)
Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin
Rohan V. Pai et al.
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY (2016)
Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers
Robert S. Wallis et al.
LANCET INFECTIOUS DISEASES (2016)
Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder
John G. Y. Chan et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)
Potential of aerosolized rifampicin lipospheres for modulation of pulmonary pharmacokinetics and bio-distribution
Charan Singh et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2015)
Pharmacokinetics of Inhaled Rifampicin Porous Particles for Tuberculosis Treatment: Insight into Rifampicin Absorption from the Lungs of Guinea Pigs
Lucila Garcia Contreras et al.
MOLECULAR PHARMACEUTICS (2015)
Toxicology Studies for Inhaled and Nasal Delivery
R. K. Wolff
MOLECULAR PHARMACEUTICS (2015)
Inhaled Dry Powder Formulations for Treating Tuberculosis
Shyamal Das et al.
CURRENT DRUG DELIVERY (2015)
Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats
Rajesh Parikh et al.
DRUG DELIVERY (2014)
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells
Veronique Dartois
NATURE REVIEWS MICROBIOLOGY (2014)
Regulatory toxicology considerations for the development of inhaled pharmaceuticals
Keith Owen
DRUG AND CHEMICAL TOXICOLOGY (2013)
Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management
Vidyasagar Ramappa et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2013)
Pulmonary delivery of dry powders to rats: Tolerability limits of an intra-tracheal administration model
A. Guillon et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2012)
Quantification of rifampicin in human plasma and cerebrospinal fluid by a highly sensitive and rapid liquid chromatographic-tandem mass spectrometric method
Abhishek Srivastava et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2012)
Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
Jakko van Ingen et al.
CLINICAL INFECTIOUS DISEASES (2011)
A new respirable form of rifampicin
Yoen-Ju Son et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2011)
Inhaled drug therapy for treatment of tuberculosis
Amit Misra et al.
TUBERCULOSIS (2011)
Pharmacokinetics and Pharmacodynamics of Controlled Release Insulin Loaded PLGA Microcapsules using Dry Powder Inhaler in Diabetic Rats
Hamed Hamishehkar et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2010)
Thermal behavior and decomposition kinetics of rifampicin polymorphs under isothermal and non-isothermal conditions
Ricardo Alves et al.
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Tuberculosis pharmacotherapy: strategies to optimize patient care
Carole D. Mitnick et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Involvement of Oxidative Stress in Increases in the Serum Levels of Various Enzymes and Components in Rats with Water-Immersion Restraint Stress
Yoshiji Ohta et al.
JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION (2009)
One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis
Katsuya Ohashi et al.
JOURNAL OF CONTROLLED RELEASE (2009)
Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems for Pulmonary Delivery
Jean C. Sung et al.
PHARMACEUTICAL RESEARCH (2009)
The current state of serum biomarkers of hepatotoxicity
Josef Ozer et al.
TOXICOLOGY (2008)
Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model
L. Garcia-Contreras et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Clinical chemistry and haematology historical data in control Sprague-Dawley rats from pre-clinical toxicity studies
C Petterino et al.
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY (2006)
Antitubercular inhaled therapy: opportunities, progress and challenges
R Pandey et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages
SP Vyas et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2004)
Solid-state characterization of rifampicin samples and its biopharmaceutic relevance
S Agrawal et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Screening in an infectious disease model
S Suarez et al.
PHARMACEUTICAL RESEARCH (2001)
分享论文
